Epidemiology and risk 629 items
Population cohorts, trial biobanks and registries: how much risk elevated Lp(a) carries for coronary disease, stroke, aortic stenosis, heart failure and mortality, in primary and secondary prevention, and how that risk sits alongside LDL-C and inflammation.
Studies
- LPA is the genome-wide signal for aortic valve calcification and stenosis (Thanassoulis et al., NEJM 2013)
- LPA variants raise Lp(a) and coronary risk: the PROCARDIS gene-chip study (Clarke et al., NEJM 2009)
- Genetically elevated Lp(a) causes myocardial infarction: the Copenhagen Mendelian randomisation (Kamstrup et al., JAMA 2009)
- Lp(a)FRONTIERS APHERESIS: pelacarsen replaces lipoprotein apheresis in 25 of 26 patients (Parhofer et al., EHJ 2026)
- Baseline and on-statin Lp(a) predict events in statin trials: patient-level meta-analysis (Willeit et al., Lancet 2018)
- How much Lp(a) lowering equals 1 mmol/L of LDL-C? The Mendelian randomisation answer (Burgess et al., JAMA Cardiol 2018)
- IONIS-APO(a)Rx and the GalNAc-conjugated APO(a)-LRx: two dose-ranging trials (Viney et al., Lancet 2016)
- Elevated Lp(a) and risk of aortic valve stenosis in the general population (Kamstrup et al., JACC 2014)
- Lp(a) and the risk of CHD, stroke and non-vascular mortality: the Emerging Risk Factors Collaboration (JAMA 2009)
- Lp(a) risk persists at the lowest achieved LDL-C: participant-level meta-analysis of six statin trials (Bhatia et al., Circulation 2025)
- ALPACAR: zerlasiran lowers time-averaged Lp(a) by more than 80 percent over 36 weeks in ASCVD (Nissen et al., JAMA 2024)
- Inflammation, cholesterol, Lp(a) and 30-year cardiovascular outcomes in women (Ridker et al., NEJM 2024)
- Lp(a) is about six times more atherogenic than LDL per particle: apoB-based Mendelian randomisation (Björnson et al., JACC 2024)
- Lp(a) and incident ASCVD in 460,506 UK Biobank participants (Patel et al., ATVB 2021)
- Alirocumab-induced Lp(a) lowering independently predicts fewer MACE after ACS: ODYSSEY OUTCOMES (Bittner et al., JACC 2020)
- Lp(a) molar concentration, not apo(a) size, drives cardiovascular risk; loss of Lp(a) raises diabetes risk: deCODE (Gudbjartsson et al., JACC 2019)
- How much Lp(a) lowering for a clinically relevant CHD reduction? The Lp(a)-GWAS-Consortium estimate (Lamina and Kronenberg, JAMA Cardiol 2019)
- Lp(a) and oxidised phospholipids drive valve calcification activity and progression in aortic stenosis (Zheng et al., JACC 2019)
- Lp(a) and myocardial infarction across seven ethnic groups: INTERHEART (Paré et al., Circulation 2019)
- Lp(a), PCSK9 inhibition and cardiovascular risk in FOURIER (O'Donoghue et al., Circulation 2019)
- The phenotypic consequences of genetically lowered Lp(a) (Emdin et al., JACC 2016)
- First antisense drug against apo(a) in humans: ISIS-APO(a)Rx phase 1 (Tsimikas et al., Lancet 2015)
- Lipoprotein apheresis cuts event rates in Lp(a) hyperlipoproteinaemia with progressive disease (Leebmann et al., Circulation 2013)
- First-degree relatives of people with elevated Lp(a) have more MACE: Swedish registry cohort (Kindborg et al., EHJ 2026)
- Lp(a) predicts coronary events but not stroke, and evolocumab benefits at any Lp(a): VESALIUS-CV (Monguillon et al., Circulation 2026)
- Coronary artery calcium still stratifies risk in people with elevated Lp(a): a four-cohort study (Bhatia et al., JACC 2026)
- Thirty-year cardiovascular risk in healthy women by Lp(a) threshold: the Women's Health Study (Nordestgaard AT et al., JAMA Cardiol 2026)
- Lp(a) and recurrent ASCVD in 273,770 US patients: risk rises continuously to a hazard ratio of 1.45 above 300 nmol/L (MacDougall et al., EHJ 2025)
- Only 13 percent of coronary patients worldwide would meet a 150 nmol/L trial threshold: INTERASPIRE (Barkas et al., JACC 2025)
- Lp(a) raises cardiovascular risk regardless of hs-CRP, in primary and secondary prevention (Small et al., JAMA Cardiol 2024)
- Lp(a) drives ASCVD, MI and aortic stenosis risk independent of C-reactive protein: Copenhagen (Thomas et al., EHJ 2023)
- Lp(a) levels in a global ASCVD population: Lp(a)HERITAGE (Nissen et al., Open Heart 2022)
- High Lp(a) accelerates low-attenuation (necrotic core) plaque progression on serial CT angiography (Kaiser et al., JACC 2022)
- An LC-MS/MS candidate reference method for standardising Lp(a) measurement (Marcovina et al., Clin Chem 2021)
- Statin therapy increases Lp(a) levels: subject-level meta-analysis of six trials (Tsimikas et al., EHJ 2020)
- Lp(a) lowering of about 50 mg/dL may be needed for a 20 percent MACE reduction in secondary prevention (Madsen et al., ATVB 2020)
- High Lp(a) and high risk of cardiovascular and all-cause mortality (Langsted et al., EHJ 2019)
- Elevated Lp(a) and risk of ischaemic stroke, observational and genetic (Langsted et al., JACC 2019)
- Oxidised phospholipids as a unifying theory for Lp(a) in ASCVD and aortic valve disease (Boffa and Koschinsky, Nat Rev Cardiol 2019)
- NLA scientific statement: use of Lp(a) in clinical practice, a biomarker whose time has come (Wilson et al., J Clin Lipidol 2019)
- A test in context: Lp(a) diagnosis, prognosis, controversies and emerging therapies (Tsimikas, JACC 2017)
- Lp(a) as a cause of cardiovascular disease: epidemiology, genetics and biology (Nordestgaard and Langsted, J Lipid Res 2016)
- Five years of lipoprotein apheresis for Lp(a)-associated disease: the German prospective follow-up (Roeseler et al., ATVB 2016)
- High Lp(a) as a possible cause of clinical familial hypercholesterolaemia (Langsted et al., Lancet Diabetes Endocrinol 2016)
- Lp(a) predicts cardiovascular disease in familial hypercholesterolaemia independent of the LDLR mutation: SAFEHEART (Alonso et al., JACC 2014)
- Low Lp(a) and large apo(a) isoforms are causally linked to type 2 diabetes (Kamstrup and Nordestgaard, Lancet Diabetes Endocrinol 2013)
- Lipoprotein(a): resurrected by genetics (Kronenberg and Utermann, J Intern Med 2013)
- Lp(a) predicts cardiovascular events in Black and White adults alike: ARIC (Virani et al., Circulation 2012)
- The mysteries of lipoprotein(a) (Utermann, Science 1989)
- IL-6 modifies Lp(a)-associated coronary risk but not aortic stenosis risk: UK Biobank (JAMA Cardiol 2026)
- Lp(a) and venous thromboembolism: a signal in premenopausal women and in postmenopausal MHT users, none in men (Ezzat et al., EHJ 2026)
- mg/dL to nmol/L: the Copenhagen formula beats the factor 2.5 in the Lp(a)HORIZON screening population (Atherosclerosis 2026)
- Oxidised phospholipids on apoB predict MACE after ACS and alirocumab abolishes the relation: ODYSSEY OUTCOMES (Tsimikas et al., Circulation 2025)
- Lp(a) and interleukin-6 are independent, additive predictors of coronary events: MESA and UK Biobank (Bhatia et al., JACC 2025)
- Twelve years of lipoprotein apheresis for Lp(a)-associated progressive ASCVD: Pro(a)LiFe (Klingel et al., Atherosclerosis 2025)
- LDL-C, Lp(a) and hs-CRP are independent and synergistic predictors of MACE, on and off statins: UK Biobank (Markus et al., EHJ 2025)
- One-time LDL-C, hs-CRP and Lp(a) screening predicts 20-year events in European men and women: EPIC-Norfolk (Kraaijenhof, Nurmohamed et al., EHJ 2025)
- PREVENT equations perform well but Lp(a) adds independent risk, most in borderline- and low-risk people: MESA and UK Biobank (Bhatia et al., JAMA Cardiol 2025)
- Elevated Lp(a) in 2.9 million Chinese adults and its association with multisite subclinical atherosclerosis (Man et al., JACC 2025)
- Aspirin use and lower CHD events in people with Lp(a) above 50 mg/dL: MESA (Bhatia et al., JAHA 2024)
- Lp(a) testing in a large US academic health system: 0.3 percent of adults over ten years (Bhatia et al., JAHA 2023)
- Lp(a) is associated with the onset but not the progression of aortic valve calcification: the Rotterdam Study (Kaiser et al., EHJ 2022)
- Sex differences in Lp(a) levels and associated risk by age: Copenhagen (Simony et al., Atherosclerosis 2022)
- Finding very high Lp(a): the case for routine assessment (Nurmohamed et al., Eur J Prev Cardiol 2022)
- Genetically elevated Lp(a) shortens parental lifespan and health span (Arsenault et al., JAMA Netw Open 2020)
- Whole-genome sequencing of Lp(a) in European and African ancestries (Zekavat et al., Nat Commun 2018)
- NHLBI working group recommendations to reduce Lp(a)-mediated risk of CVD and aortic stenosis (Tsimikas et al., JACC 2018)
- LPA variants, apo(a) isoforms and events differ by ethnicity: the Dallas Heart Study (Lee et al., Circulation 2017)
- Lp(a): the impact of ethnicity and of environmental and medical conditions (Enkhmaa et al., J Lipid Res 2016)
- Elevated Lp(a) and LPA risk genotypes raise the risk of heart failure (Kamstrup and Nordestgaard, JACC Heart Fail 2016)
- Lp(a)-lowering therapies: a promising future (Zhang, Navar, Tokgozoglu, EHJ 2026)
- Lp(a) and dementia in 539,478 people: no association with Alzheimer's or vascular dementia on continuous scales (Thomas et al., EHJ 2025)
- Lp(a) and its significance in cardiovascular disease: a review (Duarte Lau and Giugliano, JAMA Cardiol 2022)
- Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial
- Elevated hs-CRP, LDL-C and Lp(a) each independently predict 30-year stroke risk in healthy women, Women's Health Study finds (Lancet Neurol 2025)
- Lp(a) predicts not just new peripheral artery disease and carotid stenosis but their progression to limb loss and stroke, UK Biobank analysis of 460,544 people finds (Circulation 2025)
- Lp(a)-lowering therapy would be cost-effective at up to £5,500 a year in secondary prevention, UK Biobank-based health technology assessment (Atherosclerosis 2026)
- Lp(a) raises coronary event risk mainly by driving plaque burden, SCAPIS cohort of 28,529 (JACC Cardiovasc Imaging 2026)
- Combined LDL-C, Lp(a) and hsCRP identify highest ASCVD risk across ethnicities, multiethnic HELIUS cohort of 15,676 (J Am Coll Cardiol 2026)
- Lp(a), remnant cholesterol and hsCRP each independently add to MI risk prediction, UK Biobank cohort of 306,183 (Prog Cardiovasc Dis 2026)
- High Lp(a) and high BMI jointly maximize ASCVD risk, Danish and UK Biobank cohorts of 512,687 (Eur J Prev Cardiol 2026)
- Very high Lp(a) predicts earlier heart attack and 16-fold higher recurrent MI risk, matched cohort of 446 (JACC Adv 2026)
- Elevated Lp(a) more than doubles myocardial infarction risk in 16,117 US Hispanic and Latino adults, a long-underrepresented population (J Am Coll Cardiol 2025)
- Over a quarter of 17,594 US patients with premature ASCVD have Lp(a) of 125 nmol/L or above, with Black patients showing the highest levels (J Clin Lipidol 2025)
- ABO blood group A or B sharpens Lp(a)'s link to MACE in chronic coronary syndrome, replicated across two cohorts totalling over 15,500 patients (MedComm (2020) 2025)
- Very high Lp(a) predicts worse coronary plaque burden and higher risk of heart attack, revascularisation and death after angiography, over a median 16.87-year follow-up in 5,118 patients (Eur J Prev Cardiol 2025)
- High Lp(a) erases the mortality benefit of high HDL-C, especially in men, cohort of 97,396 (Coron Artery Dis 2026)
- A machine-learning model adding Lp(a) predicts 1-year ASCVD risk better than smoking or diabetes status, validated in 53,930 patients (JACC Adv 2025)
- Lp(a) of 30 mg/dL or above predicts MACE in both primary and secondary prevention, 51,934-subject Taiwanese study confirms the threshold (Eur J Prev Cardiol 2025)
- Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis
- Each 50 mg/dL rise in Lp(a) raises premature ASCVD risk by 30% in a pooled 27,756-person, multi-ethnic US cohort (Am J Prev Cardiol 2025)
- Top-quartile Lp(a) raises MACE risk 30% and limb-event risk 19% in peripheral artery disease patients, Mass General Brigham registry of 3,757 finds (Eur J Prev Cardiol 2025)
- A large multi-cohort study fails to replicate the earlier signal that aspirin cuts cardiovascular risk specifically in high-Lp(a) adults (Eur J Prev Cardiol 2025)
- Elevated Lp(a) independently predicts incident atrial fibrillation regardless of inflammatory status, 365,899-participant UK Biobank study finds (Heart Rhythm 2025)
- Lp(a) falls as liver fibrosis worsens in fatty liver disease, but cardiovascular risk stays high regardless, 56,168-patient study finds (Liver Int 2025)
- Elevated Lp(a) independently raises new-onset atrial fibrillation risk by 11%, 75,376-patient Mayo Clinic cohort finds (Eur J Prev Cardiol 2025)
- Lp(a) above 125 nmol/L predicts ischaemic stroke in men but not women, and equally across age and ethnicity, UK Biobank analysis of 353,309 finds (Am J Prev Cardiol 2025)
- High Lp(a) raises death, MI, and stroke risk by 33-50% after PCI, meta-analysis of 40,241 patients across 14 studies finds (Arch Cardiovasc Dis 2025)
- High Lp(a) raises coronary heart disease risk just as much in people with zero or one traditional risk factor as in those with two or more, 66,495-person European pooled cohort finds (Eur J Prev Cardiol 2025)
- Autoimmune disease and elevated Lp(a) combine additively to nearly double MACE risk, 353,035-person UK Biobank analysis finds (Atherosclerosis 2025)
- Top-percentile Lp(a) more than doubles cardiovascular event risk in both sexes without prior ASCVD, but confers no extra risk in women under 60, Mass General Brigham registry finds (J Am Heart Assoc 2025)
- Elevated Lp(a) plus high hs-CRP together confer the highest ASCVD risk, pooled 15,933-person ARIC/FOS/MESA analysis finds, especially in men and at intermediate baseline risk (Nutrients 2025)
- Lp(a) in the top quintile nearly doubles stroke/TIA odds and doubles cerebral injury odds in 16,333 Hispanic and Latino adults, HCHS/SOL study finds (Stroke 2025)
- High Lp(a) patients with intracranial stenosis get the most benefit from remote ischemic conditioning, RICA trial analysis of 1,286 patients finds (Neurotherapeutics 2025)
- Lp(a) of 125 nmol/L or above raises valve replacement risk 58% in calcific aortic valve stenosis, UK Biobank study of 1,962 finds (J Am Heart Assoc 2025)
- Factorial Mendelian randomisation in 385 917 UK Biobank participants finds Lp(a) lowering benefits add to, not multiply, LDL-C and lifestyle effects (Int J Epidemiol 2025)
- Genetically predicted Lp(a) tracks coronary plaque severity independent of LDL-C in nearly 23,000 Million Veteran Program participants (Eur J Prev Cardiol 2025)
- In 44,354 Korean adults, having both high Lp(a) and coronary calcium raises ASCVD odds 2.4-fold, more than either marker alone (J Clin Lipidol 2025)
- Low Lp(a) tracking with worse liver disease in cross-sectional studies is reverse causality, UK Biobank and genetic analysis of 270,004 people reveals (Clin Gastroenterol Hepatol 2025)
- Meta-analysis of 562,301 participants confirms Lp(a) raises MACE risk independent of hs-CRP in both primary and secondary prevention (JACC Adv 2024)
- German Chronic Kidney Disease study finds each 10 mg/dL rise in Lp(a) independently raises cardiovascular risk in 5,043 CKD patients (J Intern Med 2024)
- In 10,000 PCI patients, elevated Lp(a) only predicts death when LDL-C and hs-CRP are both high (Clin Cardiol 2024)
- Lp(a) above 100 mg/dL nearly doubles risk of severe degenerative aortic stenosis, but not bicuspid or rheumatic disease, in 44,742 patients (JACC Asia 2024)
- Mass General Brigham Lp(a) Registry finds diabetes plus elevated Lp(a) drives a nearly eightfold jump in annual cardiac event rate (Cardiovasc Diabetol 2024)
- In 68,748 subjects, correcting LDL-C for its Lp(a) cholesterol content adds nothing at the population level, but Lp(a) mass changes what apoB and LDL-C mean for individual risk (J Am Coll Cardiol 2024)
- In ARIC and MESA, healthier lifestyle and social determinants barely dent Lp(a)'s link to heart attack and stroke (JACC Adv 2024)
- Mass General Brigham registry finds high Lp(a) carries the same heart attack risk as having two traditional risk factors combined (J Am Heart Assoc 2024)
- Low-attenuation coronary plaque mediates 73.3% of Lp(a)'s effect on future heart attack risk in a validated 6,729-patient study (J Am Coll Cardiol 2024)
- ARISE machine-learning tool, validated across four cohorts totalling nearly 480,000 people, cuts the number needed to test for elevated Lp(a) by up to 67.3% (Nat Cardiovasc Res 2024)
- Twenty-six-year NHANES III follow-up finds regular aspirin cuts ASCVD mortality by 52% specifically in adults with elevated Lp(a) (Am J Prev Cardiol 2024)
- Pooling MESA, CARDIA, JHS, FHS and ARIC over 21 years, top-decile Lp(a) raises ASCVD risk 46% overall and 92% in people with diabetes (J Am Coll Cardiol 2024)
- BiomarCaRE project of 71,678 people finds Lp(a) predicts recurrent coronary events only in those with residual inflammatory risk (Eur Heart J 2024)
- In 16,419 Boston patients followed nearly 12 years, the Lp(a) threshold for elevated MACE risk differs between primary and secondary prevention (J Am Coll Cardiol 2024)
- Over 1 in 5 of 18,544 bypass surgery patients had high Lp(a), which raised death risk 31% and was blunted by arterial grafts (J Am Heart Assoc 2024)
- In 16,150 Chinese coronary disease patients, the lowest Lp(a) quintile, not the highest, had the most bleeding at 2 years (Thromb Haemost 2024)
- Lp(a) and family history of cardiovascular disease combine to raise heart failure risk by 42% in 299,158 UK Biobank adults (J Lipid Res 2023)
- Lp(a) above 50 mg/dL raises cardiovascular mortality risk by 83% independent of LDL cholesterol, in 275,430 Korean adults (Eur J Prev Cardiol 2023)
- Every 50 mg/dL rise in Lp(a) raises cardiovascular death risk by up to 31%, a dose-response meta-analysis of 957,253 people across 75 studies (Eur J Epidemiol 2023)
- High Lp(a) in youth (ages 9-24) doubles the risk of adult cardiovascular disease decades later, pooled data from the Young Finns Study and Bogalusa Heart Study (Circulation 2023)
- Lp(a) above 175 nmol/L explains 3% of population cardiovascular disease burden, and lowering it 80% could cut CHD risk by 24%, an analysis of 413,734 UK Biobank participants (Eur J Prev Cardiol 2022)
- Elevated Lp(a) triples stroke-recurrence risk in patients under 60, the BIOSIGNAL study of 1,733 acute stroke patients (Eur Heart J 2021)
- Low Lp(a) shows no safety signal for cancer or infection risk, reassuring news as lowering drugs advance, an analysis of 109,440 Danes (Eur Heart J 2021)
- Elevated Lp(a) raises cardiac event risk by 78% in CAD patients, a meta-analysis of 17 studies and 283,328 patients (Lipids Health Dis 2019)
- Lp(a) predicts ischemic stroke risk nearly twice as strongly in Black versus White Americans, the REGARDS study of 30,239 adults (Arterioscler Thromb Vasc Biol 2019)
- Lp(a) link to carotid plaque is strongest in white participants and weaker in Black participants, the multi-ethnic MESA study of 5,155 adults (Arterioscler Thromb Vasc Biol 2019)
- Lp(a) raises heart failure risk in white participants only, not in Black, Hispanic or Chinese participants, the MESA study of 6,809 adults (Arterioscler Thromb Vasc Biol 2018)
- Elevated Lp(a) risk fades when LDL cholesterol is below 2.5 mmol/L, an EPIC-Norfolk and Copenhagen City Heart Study analysis (Eur Heart J 2018)
- Lp(a) predicts cardiovascular risk in women only when total cholesterol is high, an analysis of over 24,000 Women's Health Study participants plus WHI and JUPITER cohorts (J Am Coll Cardiol 2018)
- Lp(a) above 50 mg/dL confers over 10-fold higher risk of heart attack, stroke or amputation in patients with existing artery disease, the FRENA registry of 1503 patients (Atherosclerosis 2018)
- Lp(a) predicts continued carotid plaque progression despite intensive LDL-lowering therapy, an AIM-HIGH trial imaging substudy of 152 patients (Arterioscler Thromb Vasc Biol 2018)
- Lp(a) in the top 25% raises abdominal aortic aneurysm risk by 57%, the ARIC study of 13,683 adults over 22 years (Atherosclerosis 2018)
- LPA gene variants triple Lp(a) levels, and the highest Lp(a) quartile raises heart attack risk by 49% in chronic kidney disease, the CRIC Study of 3744 patients (Arterioscler Thromb Vasc Biol 2017)
- Lp(a) risk is highest in Southern Europe and in people with diabetes, the BiomarCaRE consortium study of 56,804 Europeans (Eur Heart J 2017)
- Lp(a) and its gene variants predict coronary disease severity but not mortality once heart disease is established, a study of 3313 LURIC patients validated in over 106 000 (Lancet Diabetes Endocrinol 2017)
- Ideal cardiovascular health cuts the excess risk from high Lp(a) by two-thirds, the EPIC-Norfolk study of 14,051 adults (Atherosclerosis 2017)
- High Lp(a) predicts death from infection in younger dialysis patients with diabetes, the 4D Study post hoc analysis of 1255 patients (Nephrol Dial Transplant 2016)
- Lp(a) improves 15-year cardiovascular risk prediction, especially for people at intermediate risk, the Bruneck Study of 826 adults (J Am Coll Cardiol 2014)
- Lp(a) predicts heart disease risk in secondary prevention only when LDL cholesterol is elevated, a meta-analysis of 18,978 patients (J Am Coll Cardiol 2014)
- Lp(a) predicts peripheral artery disease and coronary disease but not stroke, the EPIC-Norfolk study of 18 720 adults (Arterioscler Thromb Vasc Biol 2012)
- Lp(a) predicts coronary revascularization need only when LDL cholesterol is above 70 mg/dL, a study of 2769 angiography patients (J Lipid Res 2010)
- Only extremely high Lp(a) above the 90th percentile raises cardiovascular risk in women, the Women's Health Study of 27,791 participants (JAMA 2006)
- Lp(a) above 30 mg/dL doubles coronary disease risk in women, tripling when combined with high fibrinogen or CRP, the Nurses' Health Study of 32,826 women (Eur Heart J 2005)
- Lp(a) raises heart disease risk especially in men with high LDL cholesterol, the PRIME Study of 9133 men (Atherosclerosis 2002)
- Lp(a) predicts heart disease risk in both sexes, with much stronger overall risk prediction in women, the ARIC study of 12,339 people (Circulation 2001)
- Lp(a) triples coronary risk in men with low HDL cholesterol, the PROCAM study of 788 men (J Am Coll Cardiol 2001)
- Lp(a) in the top third raises coronary heart disease risk by 60%, a meta-analysis of 27 prospective studies (Circulation 2000)
- MASLD blunts Lp(a) yet MASLD with elevated Lp(a) doubles cardiovascular risk, MESA cohort (Metabolism 2026)
- Elevated Lp(a) and insulin resistance jointly double cardiovascular mortality risk in MASLD, UK Biobank analysis of 101,348 (Cardiovasc Diabetol 2026)
- MASLD lowers Lp(a) in men and postmenopausal women but not premenopausal women, SHIP and UK Biobank cohorts (Cardiovasc Diabetol 2026)
- Lp(a) of 30 mg/dL or more predicts CKD progression and cardiovascular death, nationwide Chinese cohort study (J Clin Lipidol 2026)
- Obstructive sleep apnea raises cardiovascular risk only in ACS patients with above-median Lp(a), OSA-ACS cohort of 1137 (Sleep 2026)
- Phenotypic clustering splits high-Lp(a) patients into distinct cardiovascular risk groups, cohort of 2,355 (Sci Rep 2026)
- Lipoprotein(a) and residual cardiovascular risks in Japanese patients with coronary artery disease who achieve guideline-recommended LDL-C goals
- Elevated Lp(a) raises PAD prevalence (OR 1.81) and triples repeat revascularisation after limb procedures (J Vasc Surg 2026)
- Comparative associations of LDL-C, Lp(a), hsCRP, and IL-6 with cardiovascular risk: Insights from the UK Biobank and MESA
- Adding LAA morphology and Lp(a) to a thrombus-risk model beats CHA2DS2-VA in atrial fibrillation, cohort of 418 (Int J Cardiol Heart Vasc 2026)
- Lp(a) above 50 mg/dL raises first MI risk mainly in women with type 2 diabetes, cohort of 2,967 (Diagnostics Basel 2026)
- Lp(a) mortality risk varies by race and ethnicity in NHANES III, 22.6-year mean follow-up (Am J Cardiol 2026)
- Elevated Lp(a) raises restenosis risk 3-fold after PCI, meta-analysis of twenty-six studies (J Clin Med 2026)
- IL-6 modifies whether Lp(a) predicts cardiovascular events, UK Biobank cohort of 34,092 (Atherosclerosis 2026)
- High Lp(a) tracks with advanced coronary calcium and carotid atherosclerosis in asymptomatic patients, cohort of 3,697 (Nutr Metab Cardiovasc Dis 2026)
- Lipoprotein(a), High-Sensitivity C-Reactive Protein, and Incident ASCVD Risk in Individuals Without Standard Modifiable Risk Factors
- Sex Differences in Lipids and Lipoproteins and Their Relationship With Cardiovascular Disease: A Prospective Study of UK Biobank Participants
- Elevated Lp(a) is linked to mitral annular calcification but not regurgitation, propensity-matched study of 66,292 pairs (J Clin Lipidol 2026)
- Lp(a) raises heart failure risk in a nonlinear, plateauing dose-response pattern, meta-analysis of 400,631 (Clin Cardiol 2026)
- Joint control of LDL-C, Lp(a) and CRP erases the excess cardiovascular risk of steatotic liver disease in a 291,995-person UK Biobank cohort (Nutr Metab Cardiovasc Dis 2026)
- Elevated Lp(a) raises repeat revascularisation risk after PCI, meta-analysis of eighteen studies (Acta Cardiol 2026)
- Lp(a) tracks with coronary plaque burden but not long-term mortality in established ASCVD, combined cohort of 798 (Eur J Prev Cardiol 2026)
- Lp(a) of 50 mg/dl or more raises recurrent MACE risk 82.6% in very young acute coronary syndrome survivors, STudy of eArly Myocardial INfArction registry (Coron Artery Dis 2026)
- Linear and Nonlinear Associations Between Lipoprotein(a) and the Risks of Atherosclerotic Cardiovascular Disease
- Beyond CACS: Can Lp(a) and AI-CCTA Unmask "Invisible" Residual Cardiovascular Risk?
- Lp(a) drives adverse cardiac remodeling only in Hispanic adults, MESA cohort of 2,366 (Circ Popul Health Outcomes 2026)
- Elevated Lp(a) marks a high-risk phenotype in advanced coronary calcification, IVUS study of 292 (Int J Cardiol Cardiovasc Risk Prev 2026)
- Lp(a) and insulin resistance jointly raise cardiovascular risk 32%, UK Biobank cohort of 328,031 (J Am Heart Assoc 2026)
- Lp(a) 50 mg/dL or more raises intracranial stenosis odds 4.5-fold in ischemic stroke, cohort of 397 (J Clin Lipidol 2026)
- Lp(a) predicts ASCVD across glucose-metabolism status independent of CRP, UK Biobank cohort of 307,269 (Diabetes Obes Metab 2026)
- Elevated Lp(a) predicts mortality only in high traditional cardiovascular risk, NHANES III cohort with follow-up to 2019 (Eur J Prev Cardiol 2026)
- Elevated Lp(a) predicts higher baseline coronary plaque burden and faster low-attenuation plaque growth on serial CT angiography (Front Cardiovasc Med 2026)
- Lower Lp(a) tracks the onset and progression of fatty liver disease across three cohorts totalling over 36,000 people (Front Nutr 2026)
- Tea's benefit after coronary heart disease is greatest when Lp(a) is low and CRP is high, UK Biobank analysis of 25,306 patients finds (Front Nutr 2026)
- Dual-high Lp(a) and inflammatory-lipid index carries an 8-fold MACE risk in 1,910 ACS patients with type 2 diabetes (Front Cardiovasc Med 2026)
- High Lp(a) plus high homocysteine triples MACE risk after premature myocardial infarction in a 1,741-patient cohort, validating a '50-15' dual threshold (Front Nutr 2026)
- Elevated Lp(a) improves 20-year ASCVD risk reclassification beyond HellenicSCOREII+, two Greek cohorts (J Clin Lipidol 2026)
- Lp(a) above 50 mg/dL predicts MACE and improves SCORE2/PCE performance, ambulatory cohort of 3,052 (Clin Res Cardiol 2026)
- Cumulative Lp(a) burden, not just a single measurement, tracks with worse outcomes in 2,634 heart attack patients (Lipids Health Dis 2025)
- Rising Lp(a) independently predicts coronary plaque progression on serial IVUS despite aggressive statin therapy, in 79 CAD patients (Sci Rep 2025)
- Both very low and very high Lp(a) raise stroke recurrence risk in 3,311 diabetic stroke patients, U-shaped pattern from China's national registry finds (Diabetol Metab Syndr 2025)
- Nearly one in three Argentines has elevated Lp(a), and it predicts MACE most strongly in statin-naive patients, GAELp(a) registry of 3,000 finds (Atherosclerosis 2025)
- Elevated Lp(a) brought more cardiovascular events over 5 years and real psychosocial distress in Germany's ELITE cohort study (Lipids Health Dis 2025)
- Coronary calcium score adds prognostic value over Lp(a) in men but not women, MESA analysis of 4,651 participants finds (Circ Cardiovasc Imaging 2025)
- High Lp(a) drives greater fibrotic coronary plaque volume in men but not women on CT angiography, COPRODUCTION registry of 1,946 patients finds (Clin Res Cardiol 2025)
- Lp(a)'s link to coronary stenosis holds only under low systemic inflammation, 1,513-patient angiography study finds (Am J Prev Cardiol 2025)
- Higher Lp(a) predicts secondary events after first-time ACS, with levels highest in Indian and lowest in Māori patients, New Zealand's multi-ethnic MENZACS study finds (Atherosclerosis 2025)
- Combining Lp(a) with CT-quantified pericoronary fat inflammation sharpens MACE prediction in non-obstructive coronary disease, 1,052-patient study finds (Int J Cardiol 2026)
- Low-dose aspirin cuts heart attack risk 38% and kidney failure risk 28% in CKD patients with Lp(a) of 50 mg/dL or above, but not below it, CRIC cohort finds (JACC Adv 2025)
- Combined hormone therapy lowers Lp(a) by 5.1 mg/dL in postmenopausal women, meta-analysis of 27 trials finds (Diabetol Metab Syndr 2025)
- German men have more than double the Lp(a) of German women, and 1 in 5 adults from a pre-statin-era population exceeded 50 mg/dL, national survey finds (JACC Adv 2025)
- Patients with prior ASCVD and Lp(a) above 90 mg/dL rack up 2.5 times higher healthcare costs and more MACE than those with normal Lp(a), Alberta real-world study of 29,229 finds (Atherosclerosis 2025)
- An optimal Life's Simple 7 score cuts ASCVD risk regardless of Lp(a) level, MESA cohort of 6,676 finds, but elevated Lp(a) still carries higher absolute risk at every lifestyle score (Eur J Prev Cardiol 2025)
- Lp(a)'s link to MACE is significantly stronger in atherosclerotic patients with type 2 diabetes than without, 25,826-patient Korean cohort finds (Eur J Prev Cardiol 2025)
- Elevated Lp(a) does not predict new or progressing coronary calcium, large 41,929-person Korean cohort finds, challenging a common risk-marker assumption (Eur J Prev Cardiol 2025)
- One in four South Asians has Lp(a) above 50 mg/dL, helping explain heart attacks nearly a decade earlier than in Europeans, review argues (J Am Heart Assoc 2025)
- Adding Lp(a) boosts prediction of MACE and limb loss after lower-limb revascularisation in diabetic CLTI patients, pushing model AUC as high as 0.98 (Cardiovasc Diabetol 2025)
- Elevated Lp(a) independently predicts ventricular arrhythmias, even after adjusting for ASCVD, TriNetX cohort of over 116,000 patients finds (Heart Rhythm O2 2025)
- Higher Lp(a) predicts obstructive coronary disease only in asymptomatic people with diabetes, not without, 7,201-person CCTA study finds (Sci Rep 2025)
- Elevated Lp(a) is significantly higher in diabetic retinopathy, and higher still in its proliferative form, meta-analysis of 7,007 subjects finds (Medicina (Kaunas) 2025)
- Phenotypic clustering splits high-Lp(a) patients into four ASCVD-risk subgroups, RED-CARPET study of 11,629 (Clin Res Cardiol 2026)
- Elevated Lp(a) tracks with vulnerable intracranial plaque features on high-resolution MRI and a 2.65-fold higher stroke recurrence risk (Eur Radiol 2025)
- Adding Lp(a) to standard risk models improves coronary disease reclassification by up to 42% in patients without modifiable risk factors, BioHEART-CT study of 1,718 finds (Eur J Prev Cardiol 2025)
- High Lp(a) predicts carotid atherosclerosis but not all-cause mortality over nearly three decades of follow-up, Toulouse cohort of 11,990 finds (Am J Prev Cardiol 2025)
- Elevated Lp(a) predicts heart failure in White but not Black participants, pooled 16,771-person ARIC/MESA/FOS analysis finds, largely via prior heart attack (J Am Heart Assoc 2025)
- Lp(a)'s coronary risk is amplified in patients with high cholesterol or triglycerides, but not for aortic stenosis or stroke, UK Biobank study of 127,958 finds (Am J Prev Cardiol 2025)
- Lp(a) does not predict limb events after CLTI revascularisation, but predicts all-cause death once kidney function is accounted for, BEST-CLI substudy finds (J Am Heart Assoc 2025)
- Elevated Lp(a) nearly triples the odds of significant white matter damage in young stroke patients, 217-patient study finds an AUC of 0.81 (J Neurol 2025)
- Lp(a) above 15 mg/dL raises 1-year MACE risk 68% after stroke or TIA, specifically in atherothrombotic subtype, Japanese cohort of 533 finds (Atherosclerosis 2025)
- Higher Lp(a) predicts worse long-term outcomes after heart attack, especially in women and patients with diabetes or hypertension, meta-analysis of 30,027 patients finds (Rev Cardiovasc Med 2025)
- Elevated Lp(a) raises stroke recurrence odds by 69% and poor functional outcome odds by over 2-fold, meta-analysis of 17,903 patients finds (J Stroke 2025)
- One in four Russians has Lp(a) above 30 mg/dL, and levels run higher in women, 73,763-patient national cohort finds (Kardiologiia 2025)
- IL-6, not hsCRP, unmasks Lp(a)- and oxidised-phospholipid-associated cardiovascular risk in the LoDoCo2 placebo arm (Atherosclerosis 2025)
- Elevated Lp(a) more than doubles arterial stroke risk in children and youth, meta-analysis of 9,923 young patients finds (J Cardiovasc Med (Hagerstown) 2025)
- Lp(a) 30 mg/dL or more predicts cardiovascular death or HF hospitalization, cohort of 1,088 (J Card Fail 2026)
- High Lp(a) raises diabetic nephropathy risk 64% in type 2 diabetes, meta-analysis of 15 studies finds (Horm Metab Res 2025)
- Diabetes and elevated Lp(a) interact multiplicatively, giving patients with both a 2.57-fold coronary heart disease risk, MESA study of 6,668 finds (Atherosclerosis 2025)
- Only 1 in 4 aortic stenosis patients has high Lp(a), limiting how many could benefit from future Lp(a)-lowering therapies, 162-patient Canadian valve clinic study finds (JACC Adv 2025)
- High Lp(a) is linked to diabetic peripheral neuropathy in Asian but not European studies, meta-analysis of 18,022 type 2 diabetes patients finds (Diabetol Metab Syndr 2025)
- Meta-analysis of 20,271 patients finds Lp(a) above 30 mg/dL more than quadruples ASCVD risk in diabetics (Cardiovasc Diagn Ther 2025)
- Measured Lp(a) molar concentration outperforms LPA genetic variants for predicting coronary disease severity in 3,779 Han Chinese patients (Lipids Health Dis 2025)
- Elevated Lp(a) predicts higher baseline plaque burden and faster low-attenuation plaque growth in 1,694 diabetic patients on serial CT angiography (Eur Radiol 2025)
- High IL-6, not hsCRP, amplifies the cardiovascular mortality risk of markedly elevated Lp(a), LURIC study of 3,316 angiography patients finds (Clin Res Cardiol 2025)
- Persistently high Lp(a) from admission to one year raises MACCE risk 87% after heart attack, 1,131-patient trajectory study finds (Ann Med 2025)
- Adding Lp(a) to an EHR-based ASCVD risk score reclassifies 21.3% of borderline-risk patients (Circ Genom Precis Med 2025)
- A random survival forest model beats traditional risk scores at predicting cardiovascular events in 4,369 patients with measured Lp(a) (Circ Genom Precis Med 2025)
- Elevated Lp(a) doubles cardiovascular risk in familial hypercholesterolaemia but not in familial combined hyperlipidaemia, where diabetes dominates instead, 909-patient study finds (Nutr Metab Cardiovasc Dis 2025)
- Lp(a) shows a U-shaped, not linear, relationship with MACE in 1,504 three-vessel disease ACS patients (Sci Rep 2025)
- Very high Lp(a) carries 67% higher odds of coronary stenosis in patients newly presenting with stable chest pain, Danish Dan-NICAD cohort of 4,346 finds (Am Heart J 2025)
- In MESA, elevated Lp(a) only raises ASCVD risk when waist-to-hip ratio is also high (Prog Cardiovasc Dis 2025)
- Every 45 mg/L rise in Lp(a) tracks a linear 5% increase in cardiovascular mortality among 578 acute coronary syndrome patients (Front Endocrinol 2025)
- Higher Lp(a) tertile independently predicts MACE in 399 patients with heart attack complicated by preserved-ejection-fraction heart failure (Front Cardiovasc Med 2025)
- Moli-sani cohort study finds Lp(a) above 90 mg/dL raises secondary cardiovascular event risk more than threefold, peaking in the first 18 months (Front Cardiovasc Med 2025)
- Lp(a) at or above 180 mg/dL nearly triples MACE risk even after LDL-C targets are met in diabetic ACS patients post-PCI (Sci Prog 2025)
- STAR-Lp(a) study of 2,594 patients finds Lp(a)-driven atherosclerosis risk is largely mitigated by managing obesity, diabetes and inflammation (Arch Med Sci 2025)
- Lp(a) predicts coronary artery disease regardless of family history in 4,512 Japanese patients (J Lipid Atheroscler 2025)
- Each Lp(a) tertile increase brings a premature heart attack 0.83 years earlier and adds 8 points to Gensini score, RELACS study of 774 ACS patients finds (Nutr Metab Cardiovasc Dis 2025)
- Combined elevation of Lp(a), hs-CRP and homocysteine triples stroke risk in the Multi-Ethnic Study of Atherosclerosis (Am J Prev Cardiol 2025)
- Elevated apoB is needed for high Lp(a) to raise ASCVD risk in the ARIC study (Am Heart J 2025)
- Lp(a)HERITAGE US subanalysis finds only 14% of 7,679 ASCVD patients had ever been tested, despite median Lp(a) 2.5-fold higher in Black participants (J Clin Lipidol 2025)
- PCSK9 inhibitors cut MACE risk by 13% while lowering Lp(a) alongside LDL-C, meta-analysis of 12 RCTs and 48,116 coronary patients finds (Coron Artery Dis 2025)
- Elevated Lp(a) independently predicts long-term in-stent restenosis in 1,209 Mayo Clinic PCI patients over nearly 9 years (Eur J Prev Cardiol 2024)
- Lp(a) predicts cardiovascular events specifically in very-high-risk ASCVD patients, not lower-risk ones, in 9,944 Chinese patients (MedComm 2024)
- High Lp(a) roughly halves the wound-healing rate after endovascular therapy for critical limb ischaemia, 280-patient study finds (Circ J 2025)
- Meta-analysis of fourteen studies confirms elevated Lp(a) raises MACE, mortality, MI and revascularisation risk in ischaemic heart disease (Cureus 2024)
- Meta-analysis of 11,958 stroke patients finds high Lp(a) more than doubles the odds of poor functional recovery, strongest soon after stroke (Eur J Neurol 2024)
- UK Biobank observational and Mendelian randomisation analyses find Lp(a) raises abdominal aortic aneurysm risk independent of ApoB (medRxiv 2024)
- Kamstrup and colleagues quantify Lp(a) as a causal risk factor for peripheral artery disease and abdominal aortic aneurysm using CGPS and UK Biobank data (Curr Opin Cardiol 2024)
- PROMISE trial analysis of 1,815 patients finds elevated Lp(a) predicts obstructive coronary disease regardless of LDL-C control, but not high-risk plaque (Am J Cardiol 2024)
- Elevated Lp(a) predicts both coronary disease severity and 7-year MACE risk in 4,332 patients with type 2 diabetes (Heliyon 2024)
- Highest Lp(a) quartile carries 19% higher MACE risk and 57% higher mortality in 8,382 Chinese hospitalised cardiovascular patients (Eur J Med Res 2024)
- Bidirectional Mendelian randomisation confirms Lp(a) causally raises chronic kidney disease risk, not the reverse (Ren Fail 2024)
- NHANES III analysis finds high Lp(a) plus high fibrinogen together carry a 2.4-fold higher cancer mortality risk, not just cardiovascular risk (BMC Public Health 2024)
- Meta-analysis of 27 RCTs finds lower saturated-fat diets modestly raise Lp(a), especially when SFA is swapped for carbs or trans fats (Am J Clin Nutr 2024)
- Miami Heart Study finds elevated Lp(a) predicts coronary plaque even in 1,200 asymptomatic adults with a zero calcium score (Circ Cardiovasc Imaging 2024)
- Meta-analysis of 227,178 subjects finds the highest Lp(a) concentrations carry 37% lower risk of incident type 2 diabetes (Horm Metab Res 2024)
- LipidCardio study of 975 angiography patients finds Lp(a) above 150 nmol/L doubles chronic total occlusion rates and lifts Gensini scores (Eur J Prev Cardiol 2024)
- Kamstrup, Nordestgaard and colleagues propose minimum data standards to harmonise future Lp(a) observational research (Eur J Prev Cardiol 2024)
- Meta-analysis of 45,059 PCI patients confirms elevated Lp(a) raises MACE risk by 38% and cardiovascular death by 58% (Cureus 2024)
- Meta-analysis of 100,540 participants finds elevated Lp(a) more than doubles premature ASCVD risk, strongest in South Asians (Eur Heart J Open 2024)
- Lp(a) at or above 30 mg/dL plus carotid plaque together carry a 4.18-fold ASCVD risk over 11.5 years in 5,471 participants (J Am Heart Assoc 2024)
- Elevated Lp(a) plus a family history of coronary disease nearly doubles MACE risk in 6,056 chronic coronary syndrome patients (J Atheroscler Thromb 2024)
- Patients with high Lp(a) but low LDL-C carry over 9 times the ASCVD risk of those with the opposite lipid profile, 8,510-patient study finds (Angiology 2025)
- First demonstration that combining Lp(a) with fibrinogen nearly quintuples stroke risk in 8,263 coronary disease patients (Eur J Clin Invest 2024)
- In 10,435 PCI patients, Lp(a)'s cardiovascular risk sharpens as kidney function worsens and nearly vanishes with normal kidneys (Clin Kidney J 2024)
- Lipoprotein(a) interacts with albuminuria, not eGFR, to raise chronic kidney disease risk in 329,415 UK Biobank participants (JMIR Public Health Surveill 2024)
- Combining Lp(a) and fibrinogen improves all-cause mortality prediction in 43,367 coronary artery disease patients (Technol Health Care 2024)
- Lp(a) improves 20-year cardiovascular risk reclassification beyond the Framingham and Reynolds scores, the ATTICA study (J Clin Lipidol 2024)
- Combined elevation of Lp(a) and Lp-PLA2 raises 1-year stroke recurrence risk in 10,675 ischaemic stroke and TIA patients (J Clin Lipidol 2024)
- Non-Hispanic Black and Hispanic patients are tested for Lp(a) far less often than white patients despite higher levels, in 56,833 US medical records (J Clin Lipidol 2024)
- Elevated Lp(a) independently predicts major adverse cardiovascular events and mortality after acute coronary syndrome, a meta-analysis of 18,168 patients (Front Cardiovasc Med 2024)
- UK Biobank study of 32,537 patients finds elevated Lp(a) raises subsequent MACE risk most sharply in the first year after an ASCVD diagnosis (Atherosclerosis 2024)
- Elevated Lp(a) is associated with both the prevalence and progression of coronary artery calcification, a meta-analysis of 40,073 individuals (Atherosclerosis 2024)
- Elevated Lp(a) triples recurrent cardiovascular event risk in coronary patients with prediabetes or diabetes, across 5,257 patients (J Endocrinol Invest 2024)
- Adding Lp(a) to the Pooled Cohort Equations meaningfully improves 10-year ASCVD risk reclassification, especially in low-risk individuals, in 6,639 MESA participants (Atherosclerosis 2023)
- Elevated Lp(a) (>=200 nmol/L) raises cardiovascular event risk by 33% in a cohort mirroring the OCEAN(a)-Outcomes trial population, 3,142 patients (Eur Heart J Open 2023)
- Lp(a) above 50 mg/dL raises carotid plaque risk by 30% in a Chinese population distribution study of 411,634 adults (Atherosclerosis 2023)
- Elevated Lp(a) (>30 mg/dL) raises long-term MACE risk by 31% after PCI for in-stent restenosis, in 2,086 patients (J Clin Lipidol 2023)
- Unlike LDL-C, Lp(a) is not associated with baseline coronary artery calcium and only modestly predicts its progression, in 5,597 MESA participants (J Clin Lipidol 2023)
- Lp(a) independently predicts diabetic nephropathy with extreme statistical certainty in 6,993 type 2 diabetes patients (Front Endocrinol 2023)
- Every 10 mg/dL rise in Lp(a) raises peripheral artery disease risk by 6%, a dose-response meta-analysis of 565,209 people across 68 studies (Eur J Med Res 2022)
- Elevated Lp(a) (>=50 mg/dL) raises coronary heart disease risk regardless of LDL-C level, in 4,585 MESA participants (Atherosclerosis 2022)
- Menopause raises Lp(a) by 3.77 mg/dL, though ageing itself cannot be ruled out as the driver, a meta-analysis spanning 12,960 women (Maturitas 2023)
- Elevated Lp(a) raises limb amputation risk more than 20-fold in peripheral artery disease, a systematic review of 493,650 subjects across 15 studies (Vasc Med 2022)
- Elevated Lp(a) plus a coronary calcium score of 100+ carries a 4.7-fold higher cardiovascular risk than either alone, in MESA and Dallas Heart Study participants (J Am Coll Cardiol 2022)
- Lp(a) above the 90th decile raises coronary artery disease risk by 62% in routinely tested patients, a 14-year Swedish follow-up of 23,398 people (Eur J Prev Cardiol 2022)
- Very high Lp(a) (>100 mg/dL) predicts multivessel coronary disease and a stepwise rise in in-hospital mortality after heart attack, the French RICO survey of 1,213 patients (J Clin Lipidol 2022)
- Lp(a) predicts coronary disease and its severity across ethnicities, highest in Asian Indians, in a multi-ethnic study of 2,025 Southeast Asian patients (Atherosclerosis 2022)
- Lp(a) in the top quartile raises subclinical coronary plaque odds by up to 67%, in 7,201 asymptomatic individuals undergoing CT angiography (Atherosclerosis 2022)
- Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
- Elevated Lp(a) raises ischaemic stroke risk and specifically large-artery atherosclerosis stroke, a meta-analysis of 40,012 people across 41 studies (Sci Rep 2021)
- Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial
- Elevated Lp(a) and family history combine for a 43% higher cardiovascular risk than either alone, in 12,149 ARIC participants (J Am Coll Cardiol 2020)
- High Lp(a) independently raises cardiovascular mortality risk in 1492 peritoneal dialysis patients (J Clin Lipidol 2020)
- 1 in 7 Americans has Lp(a) above the risk threshold, and Lp(a) predicts heart attack but not stroke in a nationally representative cohort of 8214 (J Clin Lipidol 2020)
- Higher Lp(a) predicts cardiovascular events in 393 Chinese patients with familial hypercholesterolaemia despite statin treatment (Atherosclerosis 2019)
- Lp(a) in the highest tertile raises stroke risk by 34% in a prospective cohort of 8500 Chinese adults (Atherosclerosis 2019)
- Lp(a) does not predict future venous thromboembolism risk, a Finnish cohort of 2180 men pooled with 66,583 participants across 5 studies (Scand Cardiovasc J 2019)
- Lp(a) predicts additional cardiovascular risk in people with diabetes or prediabetes, the ARIC study of 9,871 adults (Atherosclerosis 2019)
- Finns have about 50% lower Lp(a) than Central Europeans, with known genetic variants explaining 71.8% of the gap, a study of 12,284 participants (Arterioscler Thromb Vasc Biol 2018)
- Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial
- Elevated Lp(a) predicts higher coronary calcium scores in healthy relatives of patients with premature heart disease, a study of 937 family members (J Clin Lipidol 2018)
- Elevated Lp(a) triples acute coronary syndrome risk in adults under 45, but the link fades after 60, a case-control study of 1457 ACS patients (Atherosclerosis 2018)
- Lp(a) predicts heart failure hospitalization, but the link disappears once prior heart attacks are excluded, the ARIC study of 14,154 adults (Atherosclerosis 2017)
- Lp(a) is linked to a 56% higher risk of venous thromboembolism, though the effect is small, a meta-analysis of 14 studies and over 14,000 patients (Semin Thromb Hemost 2017)
- Lp(a) predicts carotid artery thickening only in HIV-infected young women, the Women's Interagency HIV Study of 250 participants (Arterioscler Thromb Vasc Biol 2017)
- Low Lp(a) below 7 mg/dL, not high Lp(a), raises type-2 diabetes risk, the Bruneck study combined with a meta-analysis of 74,575 people (Cardiovasc Diabetol 2017)
- Lp(a), not apo(a) size, independently predicts unexplained stroke in young white adults, a case-control study of 255 stroke patients (Atherosclerosis 2016)
- Lp(a) predicts diabetic retinopathy, with a five-fold higher risk when combined with poor glucose control, a prospective cohort of 787 patients with type 2 diabetes (J Clin Lipidol 2016)
- Lp(a) raises ischemic stroke risk by about a third, especially in younger patients, a meta-analysis of 20 studies and 90,904 subjects (Atherosclerosis 2015)
- Higher Lp(a) is linked to lower diabetes risk in a Chinese cohort of 10,122 adults (J Lipid Res 2015)
- Elevated Lp(a) predicts stent restenosis, especially in Asian patients, a meta-analysis of 9 studies and 1834 patients (Atherosclerosis 2013)
- HIV disease control raises apo(a) levels tied to atherogenic small isoforms, a study of 139 white and 168 Black HIV-positive patients (Arterioscler Thromb Vasc Biol 2013)
- High Lp(a) independently predicts polyvascular disease in patients undergoing bypass surgery, a Korean study of 470 patients (Atherosclerosis 2011)
- The highest Lp(a) quartile raises the risk of combined intracranial and extracranial artery narrowing five-fold in stroke patients, a Korean study of 1012 patients (Atherosclerosis 2010)
- Lp(a) more than triples ischemic stroke risk in the elderly, a Greek case-control study of 163 stroke patients and 166 controls (Atherosclerosis 2006)
- Lp(a) predicts intermittent claudication more strongly in women than men, the Edinburgh Artery Study of 1592 adults (Atherosclerosis 2001)
- Lp(a) does not predict peripheral artery disease, unlike CRP and the cholesterol ratio, a study of 14,916 physicians (JAMA 2001)
- Elevated Lp(a) unexpectedly raises coronary risk in older women just as strongly as in younger men, a cohort of 918 CAD and 829 non-CAD patients (Atherosclerosis 2000)
- Lp(a) and homocysteine together raise coronary risk nearly 5-fold in women, but not men, a study of 750 men and 403 women (Arterioscler Thromb Vasc Biol 2000)
- Lp(a) predicts ASCVD, coronary disease and prior MI but not stroke, 23,654-person Polish real-world cohort (J Clin Lipidol 2026)
- Lp(a) is roughly twice as prevalent in coronary heart disease patients as in the Czech general population, 2001-subject study (Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2026)
- Lp(a) is not clinically linked to atrial fibrillation, meta-analysis of 16 observational and 7 Mendelian randomisation studies (J Clin Lipidol 2026)
- Elevated Lp(a) raises cardiovascular death risk 51% after successful CTO-PCI, 1509-patient cohort (J Cardiovasc Dev Dis 2026)
- Lp(a) tracks non-calcified plaque in men but calcified plaque in women, 7201-person asymptomatic CCTA cohort (J Cardiol 2026)
- Preoperative Lp(a) of 30 mg/dL or more doubles 1-year stroke risk after intracranial stenting, 405-patient registry (Neurologist 2026)
- Elevated Lp(a) is not linked to dementia risk in a 151,117-patient propensity-matched real-world cohort (Eur J Intern Med 2026)
- Lp(a) of 75 nmol/L or more predicts worse neurological outcome after ischemic stroke, Spanish cohort of 300 (Clin Investig Arterioscler 2026)
- Higher Lp(a) grade tracks with CAD, PAD, retinopathy and CKD but not stroke in Japanese type 2 diabetes, cohort of 1,465 (J Atheroscler Thromb 2026)
- Aspirin shows no clear cardiovascular benefit in elevated Lp(a) or high-risk LPA genotypes, meta-analysis of 6 studies (Eur J Prev Cardiol 2026)
- High Lp(a) raises coronary heart disease risk only alongside high hsCRP in a 4128-person Chinese cohort (Clin Chim Acta 2026)
- Lp(a) above 31.2 mg/dL raises poor 3-month stroke outcome risk 79%, cohort of 175 (Brain Behav 2026)
- Elevated Lp(a) predicts higher 6-month MACE risk after myocardial infarction, Bosnian cohort of 150 (Med Sci Basel 2026)
- Aspirin shows no overall MACE benefit in elevated Lp(a) but a signal in rs3798220 carriers, meta-analysis of seven studies (Am J Cardiovasc Drugs 2026)
- Elevated Lp(a) raises cardiovascular risk mainly when homocysteine is also high, coronary disease cohort of 530 (BMC Cardiovasc Disord 2026)
- About 1 in 10 Finnish adults has elevated Lp(a), nationally representative survey of 5,484 (Lipids Health Dis 2026)
- Lp(a) lowers type 2 diabetes risk only in severe prediabetes, UK Biobank analysis (Diabetes Metab Syndr 2026)
- High Lp(a) raises AMI risk most in older women, case-control study of 2,946 patients (J Int Med Res 2026)
- Lp(a) tracks coronary stenosis severity and Gensini score, Chinese angiography cohort of 778 (Rev Cardiovasc Med 2026)
- High Lp(a) predicts worse outcomes but poor discrimination after drug-eluting stent PCI, meta-analysis of 27,618 (J Clin Lipidol 2026)
- Lp(a) is higher in Japanese coronary disease patients than controls, comparative study of 3,710 (Circ Rep 2026)
- Women have higher Lp(a) than men in acute coronary syndrome, Portuguese cohort of 388 (Rev Port Cardiol 2026)
- Preoperative Lp(a) of 30 mg/dL or more independently predicts peri-procedural stroke after intracranial stenting (Neurol Res 2026)
- High Lp(a) predicts worse long-term outcomes after STEMI in Japanese patients, 868-patient cohort (Circ J 2026)
- Lp(a) does not track with carotid thickness or stenosis despite its stroke-risk link, BIOSIGNAL cohort of 1,161 (Lipids Health Dis 2026)
- Lp(a) contributes 15% of circulating apoB in Asian healthcare workers with very high Lp(a), cohort of 1,927 (Lipids Health Dis 2026)
- Lp(a) predicts recurrent ACS despite negative fractional flow reserve testing, Chinese cohort of 513 (Rev Cardiovasc Med 2026)
- Elevated Lp(a) raises MACE risk up to 4.3-fold after PCI, systematic review of 23,421 patients (Cureus 2026)
- Lp(a) drives residual cardiovascular risk after ACS, with RNA therapies pending outcome-trial confirmation, review (J Clin Med 2026)
- Lp(a) and an LDL subfraction synergistically predict MACE after ACS, cohort of 2,061 (Angiology 2026)
- Lp(a) doubles peripheral arterial disease risk in type 2 diabetes, cohort of 590 (Br J Hosp Med Lond 2026)
- LDL-C targets are met in only a fifth of very-high-Lp(a) patients despite statins, Spanish lipid-unit study of 265 (Clin Investig Arterioscler 2026)
- Elevated Lp(a) links to multivessel disease and high coronary calcium across two Spanish prevention cohorts of 1,043 (Am J Prev Cardiol 2026)
- Cumulative LDL-C and Lp(a) predict coronary disease in statin-naive elderly, Turkish cohort of 202 (Turk Kardiyol Dern Ars 2026)
- Higher Lp(a) predicts contrast-induced nephropathy risk in 928 diabetic patients undergoing coronary angiography (Front Cardiovasc Med 2026)
- Low early-pregnancy Lp(a) independently predicts gestational diabetes in a 14,527-woman cohort (Front Endocrinol (Lausanne) 2026)
- A Kazakhstani angiographic cohort finds obstructive coronary disease risk rising at Lp(a) of just 37 nmol/L, well below Western thresholds (Front Med (Lausanne) 2026)
- Lp(a) shows no significant link to MASLD, meta-analysis of 21 studies and 418,755 (Front Nutr 2026)
- High Lp(a) more than doubles the risk of death and progression in 364 pancreatic cancer patients (BMC Gastroenterol 2025)
- Lp(a) rises after 50 in women and 60 in men, Polish reference study of 1,046 adults and 276 children (Biochem Med Zagreb 2026)
- Combining Lp(a) with the Suita score improves high-risk plaque prediction in Japanese patients, cohort of 272 (J Atheroscler Thromb 2026)
- Lp(a) and PCSK9 are markedly elevated in first ACS but don't track coronary severity, Indian cohort of 160 (Int J Cardiol Cardiovasc Risk Prev 2026)
- LDL-C in the normal range cannot rule out very high Lp(a), Danish cohort of 1,346 (Lipids 2026)
- Updated meta-analysis confirms psoriasis patients have significantly higher Lp(a), with the gap twice as large in Europeans as in Asians (World J Clin Cases 2025)
- Over 30% of screened Portuguese children have intermediate or high Lp(a), real-world pediatric study finds (Clin Exp Pediatr 2025)
- In patients 75 and older with established ASCVD, inflammation predicts MACE more strongly than Lp(a), 2,333-patient Fuwai Hospital study finds (Age Ageing 2025)
- Lp(a) of 30 mg/dL or above more than quadruples multivessel disease risk in young NSTEMI, but not STEMI, patients (Biomedicines 2025)
- Nearly a quarter of a Dubai multiethnic cohort has high-risk Lp(a), independent of LDL-C, study of 746 (Int J Cardiol 2026)
- Smoking is inversely linked to Lp(a) in a Korean cohort of 146,129 (J Lipid Atheroscler 2026)
- Lp(a) tracks with subclinical coronary disease in low-risk ageing endurance athletes, but does not explain their higher CAD prevalence, Master@Heart study finds (Eur J Prev Cardiol 2025)
- High Lp(a) combined with elevated monocyte-to-HDL-C ratio predicts peripheral artery disease 9.5 years earlier, 361-patient study finds (Int J Mol Sci 2025)
- When Lp(a) dominates a patient's atherogenic particle burden, multivessel coronary disease becomes more likely, 420-patient ACS study finds (Atherosclerosis 2025)
- A systematic review of Lp(a) in Japanese cardiovascular disease patients confirms the elevated-risk association despite study heterogeneity (JACC Asia 2025)
- Higher Lp(a) and lower ApoA1 mark stroke patients whose ischaemic penumbra is preserved beyond the standard treatment window, case-control and Mendelian randomization study finds (Curr Med Chem 2025)
- Higher Lp(a) percentile predicts rising risk of atrial fibrillation recurrence after pulsed field ablation, 133-patient Ferrara study finds (J Cardiovasc Med (Hagerstown) 2025)
- Lp(a) only weakly tracks with coronary calcium, and mainly in men over 65, STAR-Lp(a) study of 528 primary prevention patients finds (J Clin Med 2025)
- Lower BMI combined with lower Lp(a) tracks with the least atrial fibrillation, and Mendelian randomization shows the two act independently (Pol Arch Intern Med 2025)
- Living with HIV is not independently linked to elevated Lp(a), Copenhagen study of 789 people with HIV and 3,156 controls finds (AIDS 2026)
- About 1 in 5 children with new-onset diabetes has abnormal Lp(a), and levels can fluctuate within months, challenging the 'measure once' assumption (J Endocr Soc 2025)
- Elevated Lp(a) links to both coronary calcification and low bone density in 310 statin-naive older adults, suggesting a shared vascular-skeletal risk marker (Turk Kardiyol Dern Ars 2025)
- Nearly 20% of tested Kazakhstani patients have elevated Lp(a), but the marker discriminates atherosclerosis poorly on its own, 3,727-patient study finds (J Clin Med 2025)
- A systematic review of 20,896 ACS-PCI patients across five countries confirms Lp(a) as a consistent predictor of recurrent ischaemic events (Rev Cardiovasc Med 2025)
- Elevated Lp(a)'s apparent link to worse 1-year outcomes in peripheral artery disease disappears after propensity matching, 1.79-million-patient TriNetX analysis finds (Am J Cardiol 2026)
- A lifespan review traces Lp(a)'s clinical relevance from early vascular dysfunction markers in children to MI, stroke and valve disease in adults (J Clin Med 2025)
- Higher Lp(a) independently predicts cognitive impairment after ischaemic stroke, 790-patient Chinese study finds (Br J Hosp Med (Lond) 2025)
- Nearly 30% of Irish lipid-clinic patients have Lp(a) above 125 nmol/L, largest Irish distribution study finds, with levels higher in women (Ir J Med Sci 2025)
- Systemic sclerosis patients have higher Lp(a) and triglycerides but lower HDL-C than healthy controls, meta-analysis of over 2,500 participants finds (Rheumatol Int 2025)
- Lp(a) above 50 mg/dL independently flags complex coronary disease with 75% specificity in a 688-patient North Indian ACS cohort (Cureus 2025)
- Serum Lp(a) rises with disease severity and correlates with bile acid levels in intrahepatic cholestasis of pregnancy, 156-patient study finds (J Obstet Gynaecol Res 2025)
- Elevated Lp(a) combined with a high monocyte count carries the greatest risk of carotid plaque progression in premature coronary disease, 102-patient study finds (Diseases 2025)
- First-trimester Lp(a) elevation raises preeclampsia risk more than fourfold, 150-woman prospective cohort finds (J Clin Med 2025)
- Lp(a) of 50 mg/dL or above predicts MACE but not cardiovascular death after rotational atherectomy, unless it exceeds 68.3 mg/dL, 494-patient study finds (Catheter Cardiovasc Interv 2025)
- Lp(a) of 30 mg/dL or above predicts faster growth of untreated ('non-culprit') plaques after ACS, OCT-based study of 177 patients finds (Catheter Cardiovasc Interv 2025)
- Over a quarter of suspected FH patients at a lipid clinic have high-risk Lp(a), which tracks with coronary disease but not carotid plaques, 220-patient study finds (Clin Cardiol 2025)
- East Asians have lower Lp(a) on average, but even modest elevations still raise ASCVD risk, comprehensive review of Asian populations finds (J Lipid Atheroscler 2025)
- Lp(a) is firmly linked to large-artery atherosclerotic stroke, but its role in other stroke subtypes stays inconsistent, review of pathways and emerging therapies finds (J Clin Med 2025)
- PCSK9 inhibitors cut post-PCI coronary slow flow and cardiovascular events in STEMI patients with CKD and elevated Lp(a), 323-patient study finds (Catheter Cardiovasc Interv 2025)
- Aggressive lipid-lowering achieved similar LDL-C targets regardless of Lp(a) level in 263 peripheral artery disease patients, with no excess amputation or death at high Lp(a) (Lipids Health Dis 2025)
- Lp(a) of 30 mg/dL or above raises coronary heart disease risk but not stroke risk in Japan's Suita Study of 5,138 adults (J Atheroscler Thromb 2025)
- Elevated Lp(a) predicts periprocedural stroke and later ACS after carotid endarterectomy but not restenosis, systematic review of 1,450 patients finds (J Clin Med 2025)
- Highest-tertile Lp(a) independently predicts both cardiovascular and all-cause mortality in 200 Chinese hemodialysis patients (Int Urol Nephrol 2025)
- Higher Lp(a) linearly tracks with lower fatty liver disease risk, NHANES III analysis of 2,308 people confirms (Sci Rep 2025)
- Adding Lp(a) to standard risk factors raises coronary calcium prediction accuracy from 0.741 to 0.755 in elderly diabetics, 486-patient study finds (Rev Cardiovasc Med 2025)
- Elevated Lp(a) compounds subclinical atherosclerosis risk specifically in diabetic chest-pain patients in China (Cardiovasc Diagn Ther 2025)
- Lp(a) and fibrinogen act synergistically on carotid plaque in 3,913 Chinese coronary artery disease patients (Eur J Med Res 2025)
- First report links elevated Lp(a) to aortic root dilatation specifically in hypertensive patients, in 513 inpatients (Echocardiography 2025)
- Elevated Lp(a) cuts 24-month event-free survival after PCI from 91.76% to 74.13% in 360 patients (Cureus 2025)
- Unbiased clustering of 661 Portuguese adults reveals a distinct high-Lp(a) profile: older, male, hypertensive and diabetic (Front Cardiovasc Med 2025)
- Even mildly elevated Lp(a) doubles coronary heart disease risk in 591 patients with early-onset type 2 diabetes (Front Endocrinol 2025)
- Lp(a) above the 90th percentile predicts recurrent ischaemic stroke in 2,029 patients with type 2 diabetes but not in those without it (Diabetes Metab Syndr Obes 2025)
- Lp(a) at or above 50 mg/dL tracks with younger heart attacks and more diseased coronary vessels in 189 early-onset MI patients (Arch Cardiol Mex 2025)
- First large-scale Brazilian data: median Lp(a) is 13.90 mg/dL in women versus 11.58 mg/dL in men across 115,197 subjects (PLoS One 2025)
- IVUS study links elevated Lp(a) to more neoatherosclerosis and a 3.4-fold higher odds of stent edge restenosis after PCI (Int J Gen Med 2025)
- In 2,247 Chinese T2DM patients, the combination of low adipose insulin resistance and high Lp(a) carries the lowest MASLD risk (Endokrynol Pol 2025)
- Lp(a) at or above 70 nmol/L on admission nearly doubles two-year mortality in 520 hospitalised ischaemic heart disease patients (Front Endocrinol 2025)
- Lp(a) above 40 nmol/L predicts ASCVD and coronary disease in 2,341 Thai patients (Vasc Health Risk Manag 2025)
- Review consolidates the case for Lp(a) as a causal driver of ASCVD and aortic valve stenosis behind three major guideline bodies (Curr Cardiovasc Risk Rep 2025)
- Meta-analysis of forty-one studies finds Lp(a) nearly 12 mg/dL higher in pre-eclampsia, but not in gestational diabetes (Prog Cardiovasc Dis 2025)
- Elevated Lp(a) independently predicts lipid-rich, vulnerable coronary plaque on OCT in 202 ACS patients (Catheter Cardiovasc Interv 2025)
- Lp(a) above 90 mg/dL predicts recurrent heart attack almost fourfold in women over 65, but shows no overall mortality link (Diagnostics 2025)
- Combining Lp-PLA2 with Lp(a) outperforms either marker alone for predicting stroke recurrence in 580 ischaemic stroke patients (J Clin Lab Anal 2024)
- Meta-analysis of 11 studies links high Lp(a) to a doubled risk of diabetic retinopathy in type 2 diabetes (Int Ophthalmol 2024)
- Lp(a) is elevated in people with HIV and inversely tracks with coronary endothelial function, a possible driver of HIV-associated cardiovascular risk (J Am Heart Assoc 2024)
- Once LDL-C is controlled below 70 mg/dL after PCI, elevated Lp(a) no longer predicts MACE or death, 878-patient Mayo Clinic study finds (Coron Artery Dis 2025)
- Lp(a) and hs-CRP rise with age specifically in Chinese T2DM patients who also have coronary disease, across 900 participants (Heliyon 2024)
- Meta-analysis of 74,691 individuals finds Lp(a) similar between NAFLD patients and controls overall, but lower in NAFLD when measured by nephelometry (J Gastroenterol Hepatol 2024)
- A machine-learning decision tree using LDL-C, CHD status, family history and age identifies clusters with up to 91.1% prevalence of elevated Lp(a) (Int J Cardiol 2025)
- Hegele group finds Lp(a) is paradoxically halved in patients with severe hypertriglyceridaemia (J Int Med Res 2024)
- STAR-Lp(a) study finds 21.5% of 2,475 outpatient cardiology patients had elevated Lp(a), more often women and those with atrial fibrillation (Pol Arch Intern Med 2024)
- Lp(a) at or above 30 mg/dL predicts multivessel coronary disease in 256 young acute myocardial infarction patients (Biomedicines 2024)
- Systematic review of 2,058 patients finds elevated Lp(a) consistently linked to vulnerable carotid plaque features (J Stroke Cerebrovasc Dis 2024)
- Lp(a) above 50 mg/dL raises incident hypertension risk in normotensive adults over 50, but not younger ones, in 5,307 patients (J Clin Hypertens 2024)
- In 195 children already followed for cardiovascular risk factors, 17% had elevated Lp(a) despite normal LDL cholesterol (Ital J Pediatr 2024)
- Lp(a) at or above 30 mg/dL predicts coronary disease in women but not men, while 50 mg/dL works for both, in 1,858 Turkish patients (Clin Cardiol 2024)
- Meta-analysis of 1,345 patients finds young stroke patients are 61% more likely to have elevated Lp(a) than age-matched controls (J Stroke Cerebrovasc Dis 2024)
- Lp(a) at or above 30 mg/L independently predicts ASCVD in 265 Beijing haemodialysis patients, alongside age, low albumin and diabetes (BMC Nephrol 2024)
- Adding Lp(a) and three other markers to the GRACE score lifts in-hospital MACE prediction AUC from 0.81 to 0.86 in 647 heart attack patients (Int J Cardiol Cardiovasc Risk Prev 2024)
- Elevated Lp(a) nearly doubles ischaemic event recurrence after cerebral vascular stenting in 553 patients (J Stroke Cerebrovasc Dis 2024)
- Cardiac CT in 207 diabetic patients links elevated Lp(a) to high-risk plaque but not to perfusion or fibrosis (Eur Radiol 2025)
- Higher Lp(a) tracks with better lung function in 679 older adults, but Mendelian randomisation finds no causal link (Biomedicines 2024)
- A larger early drop in Lp(a) after emergency PCI paradoxically predicts worse outcomes in acute coronary syndrome (World J Cardiol 2024)
- In 227 hypertensive patients, elevated Lp(a) tracks specifically with worse nocturnal blood pressure and pulse pressure patterns (Sci Rep 2024)
- Serum Lp(a) predicts aortic stiffness with an AUC of 0.77 in 148 long-term peritoneal dialysis patients (Med Sci Monit 2024)
- In a Korean longitudinal study, higher Lp(a) tertiles were associated with lower, not higher, incidence of fatty liver disease (Medicine (Baltimore) 2024)
- Nearly 19% of a Korean general-population cohort showed coronary calcium progression, and higher Lp(a) tertiles tracked with it, 2,750-person study finds (Korean J Fam Med 2025)
- High neutrophil-to-lymphocyte ratio unmasks Lp(a)'s prognostic harm after PCI, especially in women, 7,922-patient study finds (Angiology 2025)
- A new Lp(a)-inclusive risk calculator recategorised two-thirds of 671 patients upward, but an average 21 mg/dL LDL-C cut could offset most of the added risk (High Blood Press Cardiovasc Prev 2024)
- Meta-analysis of 23,105 asymptomatic patients finds elevated Lp(a) raises the odds of any coronary calcium by 31%, though evidence certainty is low (Eur J Prev Cardiol 2024)
- Swiss CoRisk cohort externally validates Lp(a) as a marker of large artery atherosclerosis stroke, but only in patients without diabetes (Swiss Med Wkly 2024)
- German LIFE Child cohort finds Lp(a) is unrelated to BMI, age or sex in 512 children, and stays stable in 94% on repeat testing (Pediatr Res 2024)
- Lipoprotein(a) is positively associated with moyamoya disease in a 1012-patient case-control study (Lipids Health Dis 2024)
- Elevated Lp(a) more than doubles ASCVD risk in an underserved, non-metropolitan German region, the WalkByLab Brandenburg study of 850 patients (Front Cardiovasc Med 2024)
- Dietary fat intake does not modify the link between Lp(a) and cardiovascular death in 22,805 US adults from ARIC and NHANES (JRSM Cardiovasc Dis 2024)
- High Lp(a) (>30 mg/dL) raises ischaemic stroke risk in atrial fibrillation patients across four adjustment models, in 2,258 propensity-matched patients (Int J Gen Med 2024)
- Lp(a) above 117 nmol/L more than doubles ischaemic stroke risk, driven by the large-artery atherosclerosis subtype, in a case-control study of 231 stroke patients (Neurol Neurochir Pol 2024)
- Concurrent high Lp(a) and hs-CRP nearly quadruples cardiovascular death risk after acute myocardial infarction in 912 patients (Front Endocrinol 2024)
- Elevated Lp(a) (>=30 mg/dL) more than quadruples risk of adverse cardiac events after PCI in 600 coronary artery disease patients (Indian Heart J 2024)
- Lp(a) rises with carotid atherosclerosis severity in 2,018 acute ischaemic stroke patients (Front Neurol 2024)
- Lp(a) testing rose 109% over five years at a UAE quaternary centre, and abnormal Lp(a) tracked with cardiovascular disease in 5,677 tested patients (Front Cardiovasc Med 2024)
- Elevated Lp(a) predicts major adverse cardiovascular events after PCI in 1,168 patients with ischaemic heart failure, especially those with obesity (Front Cardiovasc Med 2024)
- 27% of 2,001 high-risk Polish patients have elevated Lp(a), the Zabrze-Lipoprotein(a) Registry first results (Arch Med Sci 2024)
- Lp(a) distribution varies by ethnicity and sex in 521 hospitalised Singaporean patients with ischaemic heart disease (Ther Adv Cardiovasc Dis 2024)
- Review reports elevated Lp(a) affects 25% of Indians versus 1 in 5 worldwide, and correlated with severe disease in 1,021 Indian CAD patients (Indian Heart J 2024)
- Systematic review of 40,045 patients finds the Lp(a)-fatty liver relationship remains genuinely contradictory across studies (Indian J Gastroenterol 2024)
- Lp(a) does not predict carotid intima-media thickness over 20 years in 88 children without familial hypercholesterolaemia (J Clin Lipidol 2024)
- A national database of 87,379 patients confirms no link between Lp(a) and retinal vein occlusion, validating a small-cohort null finding (Can J Ophthalmol 2024)
- The HellenicSCORE II+ improves 10-year cardiovascular risk classification by 4% when stratified by Lp(a), calibrated on the ATTICA cohort (Hellenic J Cardiol 2024)
- Elevated Lp(a) predicts long-term recurrent myocardial infarction but not mortality in 1,223 AMI survivors followed a median 9.9 years (Am J Cardiol 2024)
- Sixty years after its discovery, Lp(a) still lacks a standardised assay, an approved lowering drug, or unified paediatric guidance, a review (Cells 2023)
- A healthy lifestyle lowers coronary artery disease risk regardless of Lp(a) level, though risk is highest with unfavourable habits and high Lp(a), in 4,512 Japanese patients (Eur J Clin Invest 2024)
- Elevated Lp(a) shows a consistent positive association with heart failure across 73,410 patients in 8 studies, a systematic review (Heart Fail Rev 2023)
- Elevated Lp(a) raises coronary artery calcification risk by 58% in asymptomatic adults, a meta-analysis of 12 studies (Nutr Metab Cardiovasc Dis 2023)
- A meta-analysis of 9 studies finds no overall association between Lp(a) and atrial fibrillation risk, clarifying conflicting prior evidence (Clin Cardiol 2023)
- Decreased Lp(a), unlike increased ApoB, is paradoxically linked to metabolic syndrome in a meta-analysis of 150,519 people across 50 studies (Lipids Health Dis 2023)
- Women with polycystic ovary syndrome have higher Lp(a) than controls regardless of weight, a meta-analysis of 2,337 patients across 23 studies (High Blood Press Cardiovasc Prev 2023)
- Elevated Lp(a) predicts cardiovascular events and death in chronic kidney disease patients, a systematic review of 12,260 individuals across 15 prospective studies (J Nephrol 2023)
- Lp(a) levels are significantly higher in patients with premature coronary artery disease, a meta-analysis of 11 case-control studies (Coron Artery Dis 2023)
- Elevated Lp(a) triples myocardial infarction risk in young patients, a systematic review of 9 studies screened from 334 (Int J Mol Sci 2023)
- In Chinese populations, elevated Lp(a) is linked to post-PCI thrombosis, aortic stenosis, stroke and diabetes, a review of a distinctive risk profile (Int J Biol Macromol 2023)
- Elevated Lp(a) most robustly predicts coronary events in postmenopausal women, though results are mixed for other outcomes, a systematic review of 157,690 women (Curr Probl Cardiol 2023)
- Higher Lp(a) predicts a 61% lower risk of new-onset type 2 diabetes in patients with familial combined hyperlipidaemia, a 9-year follow-up of 474 patients (J Clin Lipidol 2023)
- High Lp(a) brings cardiovascular events about 7 years earlier than high LDL alone in polygenic hypercholesterolaemia, with sex-specific patterns, in 548 patients (Front Cardiovasc Med 2023)
- Elevated Lp(a) raises cognitive impairment odds by 62% and stroke-related disability by 46% in secondary prevention ASCVD patients, a systematic review of 61 studies (PLoS One 2023)
- 13 of 17 studies link elevated Lp(a) to diabetic retinopathy risk in type 2 diabetes, a systematic review of 4,688 patients (Diab Vasc Dis Res 2023)
- Lp(a) tracks worsening kidney function and predicts advanced CKD stage in 224 patients with diabetic kidney disease (J Diabetes Complications 2023)
- No association found between Lp(a) and cardiovascular mortality in 1,222 patients with peripheral artery disease after revascularisation (Atherosclerosis 2022)
- Elevated Lp(a) (>50 mg/dL) doubles coronary event risk even in older men, a prospective study of 755 individuals followed 8 years (J Lipid Res 2022)
- Elevated Lp(a) predicts worse cardiac outcomes after acute coronary syndrome, most strongly in patients with chronic kidney disease, in 1,306 patients (Atherosclerosis 2022)
- Patients with abdominal aortic aneurysm have significantly higher Lp(a) than controls, a meta-analysis of 5,078 subjects across 11 studies (Curr Pharm Des 2022)
- High Lp(a) predicts major limb events after leg artery surgery for peripheral artery disease, in 384 Dutch patients (Atherosclerosis 2022)
- Elevated Lp(a) more than doubles retinal vein occlusion risk, a meta-analysis of 17,688 people across 13 studies (TH Open 2021)
- Lp(a) still predicts cardiovascular risk even when LDL-C is under 70 mg/dL, one of three residual-risk drivers alongside remnants and inflammation, a review (Clin Chem 2021)
- Elevated Lp(a) raises hard coronary event risk by 71% in ACS patients aged 80 and older, a study of 536 elderly patients (J Clin Lipidol 2021)
- Higher Lp(a) raises diabetic nephropathy odds by 63% in type 2 diabetes, a meta-analysis of 9,304 patients across 11 studies (Front Endocrinol 2021)
- Lp(a) above 30 mg/dL raises cardiovascular death risk by 50% in AMI patients aged 80 and older, a prospective cohort of 1,008 patients (Atherosclerosis 2020)
- Elevated Lp(a) doubles risk of declining kidney function, especially in diabetic and hypertensive patients, a prospective study of 6,257 Chinese adults (J Lipid Res 2020)
- An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial
- The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
- Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial
- A systematic review of 19 studies finds a moderate but inconsistent Lp(a)-cardiovascular disease association across primary and secondary prevention (Curr Opin Cardiol 2019)
- Lp(a) is not linked to bone density or hip fracture risk in 9698 postmenopausal women, a Women's Health Initiative post hoc analysis (BMJ Open 2019)
- Elevated Lp(a) affects 25% of South Asians and doubles to triples their coronary disease risk, a review of malignant CAD in young Indians (Indian Heart J 2019)
- Lp(a) is significantly higher in patients with abdominal aortic aneurysm, a meta-analysis of 9 studies (Angiology 2017)
- Lp(a) does not predict carotid plaque in statin-treated familial hypercholesterolaemia, a Dutch study of 191 patients (Atherosclerosis 2015)
- Lp(a) correlates with coronary disease severity only in men, not women, a study of 351 patients with established coronary atherosclerosis (Eur J Prev Cardiol 2015)
- Lp(a) correlates with the Framingham risk score in a Brazilian cohort of 400 people, the Ouro Preto Study (Atherosclerosis 2007)
- Lp(a) does not predict ischemic stroke in young women, a case-control study of 110 cases and 216 controls (Atherosclerosis 2000)
- Lp(a) does not correlate with coronary calcium in asymptomatic postmenopausal women, a study of 178 women (J Am Coll Cardiol 2000)
- Distribution of Lipoprotein(a) concentrations in children and young people with Familial Hypercholesterolemia (FH) compared to those without FH: A systematic review and narrative synthesis
- Lipoprotein apheresis: From familial hypercholesterolemia and elevated lipoprotein(a) to emerging roles in peripheral arterial and renal disease
- Combining Lp(a) and severe calcification predicts limb events after endovascular therapy for PAD, 145-patient study (Heart Vessels 2026)
- Elevated Lp(a) raises cardiovascular event odds (OR 5.3) in people living with HIV, 186-patient cohort (Clin Med Lond 2026)
- Lp(a) predicts left ventricular dysfunction in chronic total occlusion patients, 309-patient cohort (BMC Cardiovasc Disord 2026)
- First-trimester Lp(a) predicts preeclampsia, 119-woman pilot cohort (Arch Gynecol Obstet 2026)
- Common vitamin and supplement use does not shift Lp(a) over time, UK Biobank analysis of 12,109 (Lipids Health Dis 2026)
- From Phenotype to Genotype and Beyond: Insights into Familial Hypercholesterolemia and Familial Hypertriglyceridemia
- Improved diagnosis of familial hypercholesterolemia by correcting LDL-C for lipoprotein(a) in a German cohort
- Lp(a) does not predict long-term cardiometabolic risk in healthy women despite its lipid links, 387-woman cohort (Metabolites 2026)
- Lipoprotein(a) and premature myocardial infarction: Mechanistic insights and implications for PCI-era residual risk
- Lp(a) and peripheral artery disease independently stiffen arteries in hypertension, 366-patient cohort (J Clin Hypertens Greenwich 2026)
- GLP-1 receptor agonists and outcomes in obese or diabetic patients with Lp(a) above 50 mg/dL: a propensity-matched retrospective cohort (Int J Cardiol 2026)
- Lp(a) has no prognostic significance in coronary artery spasm without stenosis, 1,373-patient study (Heart Vessels 2026)
- Prevalence of Lipoprotein(a) Testing in Patients With Atherosclerotic Cardiovascular Disease Within a Large Australian Cardiology Network
- Elevated Lp(a) adds $253 million in indirect costs over 5 years in a US Markov simulation (Am J Prev Cardiol 2026)
- Lp(a) does not correlate with blood pressure in essential hypertension despite comorbidity differences, cohort of 230 (High Blood Press Cardiovasc Prev 2026)
- Elevated Lp(a) does not predict organ damage or cardiovascular events in a low-risk primary prevention cohort of 747 (High Blood Press Cardiovasc Prev 2026)
- Association of Elevated Lipoprotein(a) and Diabetes Mellitus With Survival Outcomes in Patients With Coronary Artery Disease: Findings From the CIN-II and RED-CARPET Cohorts
- Lipid-modifying efficacy and safety of obicetrapib in high-risk cardiovascular patients: A systematic review and meta-analysis
- Lp(a) is unrelated to body composition, unlike HDL-C and triglycerides, high-risk cohort of 207 (Adv Med Sci 2026)
- Elevated Lp(a) tracks with peripheral artery disease in MASLD, cross-sectional study of 468 (BMC Cardiovasc Disord 2026)
- Lipoprotein(a) in familial hypercholesterolemia
- Adding Lp(a) to the EAS risk score improves CHD reclassification in type 2 diabetes, pilot study of 90 (J Assoc Physicians India 2026)
- High-risk Lp(a) above 50 mg/dL is nearly twice as common in inflammatory bowel disease patients as in matched controls (Med Clin (Barc) 2026)
- Optimal Lp(a) cutoff for cardiovascular disease drops to 70 mg/L in diabetic patients, comparative analysis finds (Front Endocrinol (Lausanne) 2026)
- Lp(a) is significantly higher in Crohn's disease and ulcerative colitis than in healthy controls, meta-analysis of 1,978 participants finds (Ann Gastroenterol 2026)
- Lp(a) did not predict lipid-lowering therapy escalation in 431 patients, despite growing clinical interest, HELPE-R registry finds (Diseases 2025)
- Lp(a) predicts post-PCI cardiac events in coronary disease and diabetes, but evidence is inconsistent, review of four studies (Am J Med Sci 2026)
- Lp(a) rises with chronic kidney disease and independently predicts cardiovascular risk in CKD, review of emerging therapies (Clin J Am Soc Nephrol 2026)
- A meta-analysis of 20,678 atrial fibrillation patients finds modestly higher Lp(a) in those with ischaemic stroke, but flags low-certainty evidence (J Clin Med 2025)
- Serum Lp(a) predicts endothelial dysfunction in 123 hemodialysis patients, with AUC up to 0.853 for poor vascular reactivity (Ren Fail 2025)
- A 10-study meta-analysis links higher Lp(a) to atrial fibrillation itself, but with very low certainty and extreme heterogeneity (J Clin Med 2025)
- Elevated Lp(a) amplifies peripheral arterial disease risk and worsens outcomes, but apheresis remains the only approved lowering option, review finds (Rev Cardiovasc Med 2025)
- One in five hospitalised Polish patients has high Lp(a), and male sex predicts lower odds of it, cross-sectional study finds (Cardiol J 2026)
- Higher Lp(a) is linked to worse five-year recurrence-free prognosis in 296 endometrial cancer patients (Clin Lab 2025)
- Higher Lp(a) predicts carotid plaque ulceration on angiography in patients considered for carotid revascularisation (J Atheroscler Thromb 2026)
- Despite ESC guidance, Lp(a) was measured in only a third of STEMI and 15% of NSTEMI patients, and showed no link to heart failure markers, Luebeck registry finds (Atheroscler Plus 2025)
- Lp(a) is not linked to diastolic dysfunction with preserved ejection fraction, but statin therapy is protective, 1,492-patient Mayo Clinic study finds (High Blood Press Cardiovasc Prev 2025)
- Higher Lp(a) tracks with more severe coronary disease by SYNTAX score in a 51-patient South Asian angiography cohort (Cardiovasc Endocrinol Metab 2025)
- Lp(a) rose significantly 3 months after acute coronary syndrome in all 40 patients studied, challenging single-timepoint measurement (Pol Arch Intern Med 2025)
- First real-world Portuguese cohort finds 28.7% have elevated Lp(a), rising to 55.7% among those SCORE2 rates low-to-moderate risk (Lipids Health Dis 2025)
- Adding Lp(a) and an inflammation index to the TIMI score sharpens MACE prediction after STEMI in 290 patients (Int J Cardiol Heart Vasc 2025)
- Low preoperative Lp(a) independently predicts fatty liver after pancreatectomy (Anticancer Res 2025)
- Combining Lp(a) with hs-CRP raises coronary heart disease diagnostic AUC to 0.924, beating either marker alone (Am J Transl Res 2025)
- Lp(a) of 97.5 mg/L predicts coronary heart disease in type 2 diabetes, and six months of rosuvastatin does not budge it (Rev Assoc Med Bras 2025)
- In a UK NHS lipid clinic, 46% of 192 tested patients had abnormal Lp(a), with 16% at high or very high HEART UK risk (Qatar Med J 2025)
- Reduced thyroid hormone sensitivity tracks with higher Lp(a) in 1,097 euthyroid patients with type 2 diabetes (Front Endocrinol 2025)
- Lp(a) at or above 30 mg/dL predicts severe coronary stenosis with 72.5% prevalence versus 8.0% in a Vietnamese cohort (Front Cardiovasc Med 2025)
- Combining monocyte-to-HDL ratio with Lp(a) lifts in-stent restenosis prediction to an AUC of 0.860 in 190 stented patients (Front Cardiovasc Med 2025)
- Lp(a) does not predict cardiac allograft vasculopathy in 385 heart transplant recipients, unlike graft rejection history (J Clin Lipidol 2025)
- Lp(a) above 166.16 nmol/L flags severe coronary anatomy (SYNTAX score 23+) with 97% sensitivity in 173 heart attack patients (J Clin Med 2024)
- Lp(a) at or above 30 mg/dL triples myocardial infarction risk in a 106-patient case-control study (Medicina (Kaunas) 2024)
- Review argues Lp(a) testing and risk-based management should not wait for outcome-trial results (Atheroscler Plus 2024)
- In 1,193 Turkish ASCVD patients, women were eight times more likely than men to have Lp(a) above 90 mg/dL (Turk Kardiyol Dern Ars 2024)
- Hegele case series: 16 elderly patients with Lp(a) above 230 nmol/L recorded zero incident cardiovascular events over 8 years (J Int Med Res 2024)
- Amsterdam UMC case-control study finds Lp(a) above 50 mg/dL is nearly seven times more common in children with ischaemic stroke (Pediatr Blood Cancer 2024)
- Elevated preoperative Lp(a) triples the risk of shorter survival after biliary tract cancer surgery in 78 patients (Cancer Med 2024)
- Review examines Lp(a)'s paradox in diabetes: high levels compound cardiovascular risk, but low levels may themselves predict diabetes (Curr Diab Rep 2024)
- Elevated Lp(a) predicts left atrial thrombus or spontaneous echo contrast in 481 atrial fibrillation patients with low CHA2DS2-VASc scores (Lipids Health Dis 2024)
- Higher Lp(a) and TG/HDL-C ratio flag unstable carotid plaque in 142 acute ischaemic stroke patients (Brain Behav 2024)
- Saudi Arabia first Lp(a) reference intervals, median 50 nmol/L in 361 individuals, unaffected by age or sex (Diabetes Metab Syndr Obes 2024)
- 27.8% of 511 Polish cardiology and endocrinology patients have Lp(a) above 30 mg/dL, first results from the PMMHRI-Lp(a) Registry (Prog Cardiovasc Dis 2024)
- Serum Lp(a) >=300 mg/L predicts early neurological deterioration after thrombolysis for acute ischaemic stroke in 236 patients (Int J Gen Med 2024)
- A pilot study proposes a lower Lp(a) cut-off of 21.1 mg/dL for atherosclerotic risk in Kazakhstan, below the internationally recommended thresholds (Front Cardiovasc Med 2024)
- Elevated Lp(a) (>=30 mg/dL) is associated with higher sarcopenia risk in 426 patients with type 2 diabetes, regardless of sex (Diabetes Metab Syndr Obes 2024)
- High Lp(a) is associated with greater cerebral white matter hyperintensity burden in 153 stroke and TIA patients (Front Neurol 2024)
- High Lp(a) raises diabetic vascular complication risk while low Lp(a) predicts new-onset type 2 diabetes, a paradox reviewed (Expert Rev Endocrinol Metab 2024)
- Patients with elevated Lp(a) (>125 nmol/L) face very high cardiovascular risk, with early events in 65% of women and 56% of men, in 316 Spanish patients (Clin Investig Arterioscler 2024)
- One in three Ghanaian ischaemic stroke survivors has elevated lipoprotein(a), linked to female sex, diabetes and urban residence (J Neurol Sci 2024)
- Chemotherapy may raise Lp(a) in breast cancer survivors, adding cardiovascular risk on top of cancer treatment, a review (Lipids Health Dis 2023)
- Young STEMI patients have nearly double the Lp(a) of middle-aged STEMI patients in a 287-patient single-centre study (Cardiovasc J Afr 2024)
- C-peptide outperforms Lp(a) as a cardiometabolic risk predictor in type 2 diabetes, a nested case-control study of 253 participants (PLoS One 2022)
- South Asians face premature cardiovascular disease compounded by elevated Lp(a), a systematic review of 72 articles calling for early, aggressive management (Curr Probl Cardiol 2021)
- Lp(a) value for predicting recurrent events in secondary prevention remains inconsistent, a critical appraisal addressing index event bias (J Clin Lipidol 2018)
- Guidelines recommend Lp(a) testing for risk reclassification in intermediate-risk patients, a review of Lp(a)'s cardiovascular and non-cardiac disease associations (Curr Med Chem 2017)
- Only 1 of 4 studies found higher Lp(a) in migraine patients, a systematic review questioning the migraine-Lp(a) link (J Thromb Thrombolysis 2015)
- Lp(a) is not linked to cardiac allograft vasculopathy after heart transplant, 271-patient single-center cohort (J Clin Lipidol 2026)
- Lp(a) correlates with coronary disease severity (SYNTAX score, r=0.36) in an Indian angiography cohort (Ann Afr Med 2026)
- Elevated Lp(a) is associated with concentric left ventricular hypertrophy in non-diabetic hypertension: a 110-patient echocardiographic study (Blood Press 2026)
- Higher vitamin D is linked to lower Lp(a) in elite athletes, cross-sectional study of 773 (Nutrients 2026)
- Homocysteine and Lp(a) are elevated together in young-onset acute coronary syndrome, 75-patient Indian cross-sectional study (Cureus 2026)
- Lp(a) tracks coronary complexity mainly in patients under 45 with premature MI, Northeast Indian cohort of 100 (Maedica Bucur 2026)
- Impact of hypertension on associations of all-cause mortality with admission lipoprotein (a) in acute decompensated heart failure
- Lp(a) tracks with coronary disease in women but not men in a 220-patient hypercholesterolaemia cohort (Atheroscler Plus 2026)
- Uric acid and Lp(a) track with neurological damage severity in diabetic patients with penetrating-artery cerebral infarction (Pak J Pharm Sci 2026)
- Hepatic and renal function markers modulate Lp(a) variability in 153 dyslipidaemic cardiovascular patients (Front Cardiovasc Med 2026)
- In 347 Japanese ACS patients discharged alive after primary PCI, Lp(a) of 30 mg/dL or higher did not predict mid-term MACE (Int Heart J 2026)
- At a Bronx safety-net hospital, elevated Lp(a) tracked with HFpEF and higher LDL but not with other ASCVD risk factors in 78 tested patients (Heart Views 2025)
- Higher Lp(a) is an independent risk factor for type I cardiorenal syndrome in 269 coronary artery disease patients (Int J Cardiol Heart Vasc 2025)
- In 200 primary-care patients without cardiovascular disease, elevated Lp(a) tracked with neither more risk factors nor worse lipid parameters (J Clin Med 2024)
- In 130 Colombian outpatients, higher Lp(a) weakly but significantly correlated with less severe liver fibrosis (Cureus 2024)
- In patients referred for coronary angiography, elevated Lp(a) tracks with premature and multivessel coronary disease but not hypertension or obesity (Herz 2024)
- RDW, homocysteine and Lp(a) are independent risk factors for new-onset atrial fibrillation in 89 patients versus 88 controls (Eur Rev Med Pharmacol Sci 2024)
- Advanced age and higher HbA1c are linked to elevated Lp(a) in 600 cardiovascular disease patients, alongside associations with MACE and stroke (Ann Card Anaesth 2024)
- Higher Lp(a) is independently associated with diabetic nephropathy in 767 Han Chinese patients with type 2 diabetes, though discriminative value is modest (PLoS One 2024)
- Sustained high Lp(a) does not significantly increase in-stent restenosis or repeat PCI risk one year after coronary intervention, a retrospective study (Tex Heart Inst J 2024)
- Lipoprotein(a) levels do not differ in Graves' ophthalmopathy versus Graves' disease without eye involvement in 99 patients (Metab Syndr Relat Disord 2024)
- A bibliometric map of Lp(a) research finds inflammation, aortic valve stenosis and postmenopausal hormone changes as the dominant themes (Front Public Health 2022)
- Distribution of Lipoprotein(a) Levels and Clinical Associations in a Lebanese Adult Population: A Retrospective Observational Study
- Lipoprotein(a) and Cardiovascular Disease: From Genetic Risk Factor to Therapeutic Target
- Diagnostic and Severity Assessment of Coronary Artery Disease Using ApoB/ApoA-I Ratio: Insights from a Statin-Treated Eastern European Cohort
- Clinical value of Lipoprotein(a) combined with CatLet coronary score in predicting adverse events after emergency PCI for AMI patients
- Association of lipoprotein(a), oxidized phospholipids and apolipoprotein B100 in acute ischemic stroke cohort
- Genetic Prediction of Circulating Lipoprotein(a) Levels in Diverse Populations